SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Advanced Micro Devices, Inc. engages in the semiconductor business. Its products include processors, accelerators, graphics, adaptive SoCs, FPGAs, and SOMs, and software, tools, and apps. The firm offers artificial intelligence, industries, workloads, and gaming solutions. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

Advanced Micro Devices is trending as investors aggressively rotate into CPU-related AI plays following positive sector sentiment and optimistic analyst upgrades. The community is sharply divided, with bulls pointing to long-term secular growth and infrastructure dominance while bearish traders voice concerns over extreme valuation multiples, extended RSI levels, and the sustainability of this rapid parabolic move.

Dumb SEND IT

Dumb SEND IT ($DSIT) is gaining significant traction as a community-driven meme project that emphasizes rapid, collective "sending" to build momentum toward its market cap goals. The community is heavily focused on HODLing through volatility, active promotion to onboard new degens, and community-wide airdrops to reward early supporters as they aim to hit key milestones.

Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Intellia Therapeutics Inc

Intellia Therapeutics is currently surging due to the FDA lifting the clinical hold on its Phase 3 MAGNITUDE trial, signaling a significant derisking of its CRISPR-based heart disease therapy. Community discussion is dominated by bullish sentiment regarding the potential for a major short squeeze, as participants highlight the stock's high short interest and the significant valuation gap remaining since the trial's original halt.

Terra is a decentralized financial payment network that rebuilds the traditional payment stack on the blockchain. Luna is the reserve currency of the Terra platform. It has three core functions: i) mine Terra transactions through staking, ii) ensure the price stability of Terra stablecoins and iii) provide incentives for the platform’s blockchain validators.

Terra Luna Classic

Terra Luna Classic is experiencing heightened market attention as community members speculate on potential supply burns and project revivals while actively monitoring upcoming clarity legislation. Investors are engaging in spirited discussions regarding the token's long-term utility, with many holding positions in anticipation of a significant price reversal.

Atomera, Inc. engages in the development, commercialization, and licensing of proprietary processes and technologies for the semiconductor industry. It developed Mears Silicon Technology, which increases performance and power efficiency in semiconductor transistors. The company was founded by Robert Mears on November 26, 2001 and is headquartered in Los Gatos, CA.

Atomera Inc

Atomera Inc. is trending as investors aggressively speculate on imminent partnership announcements following a series of technical advancements in semiconductor materials. Community sentiment is deeply divided between long-term supporters anticipating a major licensing breakthrough and vocal critics expressing skepticism over the firm's long-standing lack of commercial revenue.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is trending as a major retail and momentum favorite, fueled by significant investor enthusiasm over potential partnerships with hyperscalers and its role in AI data center infrastructure. The community is heavily focused on a potential short squeeze, given the intense trading volume and reports of restricted share availability, while debates persist between optimistic long-term holders and bearish concerns regarding the company's current revenue levels.

The White Alien has arrived. The countdown to domination starts now.

The White Alien

The White Alien is generating significant social media momentum as community members rally behind its recent price action and viral branding. Investors are actively discussing the token's speculative potential and its cross-promotion alongside other trending crypto assets.

QUALCOMM, Inc. engages in developing and commercializing foundational technologies and products used in mobile devices and other wireless products. It operates through the following segments: Qualcomm CDMA Technologies (QCT), Qualcomm Technology Licensing (QTL), and Qualcomm Strategic Initiatives (QSI). The QCT segment develops and supplies integrated circuits and system software based on technologies for use in voice and data communications, networking, application processing, multimedia, and global positioning system products. The QTL segment grants licenses and provides rights to use portions of the firm's intellectual property portfolio. The QSI segment focuses on opening new or expanding opportunities for its technologies and supporting the design and introduction of new products and services for voice and data communications. The company was founded by Franklin P. Antonio, Adelia A. Coffman, Andrew Cohen, Klein Gilhousen, Irwin Mark Jacobs, Andrew J. Viterbi, and Harvey P. White in July 1985 and is headquartered in San Diego, CA.

Qualcomm, Inc.

Qualcomm is seeing heightened investor attention as the semiconductor sector navigates the complex intersection of AI-driven demand and supply-side constraints. Community discussions are centered on the company's long-term potential in edge AI and automotive markets versus short-term concerns regarding memory shortages and shifting handset industry dynamics.

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968, and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is seeing a historic surge, fueled by an earnings beat that shifted investor sentiment on the role of CPUs in AI infrastructure and triggered a massive short squeeze. The community is actively debating the sustainability of this parabolic move, with many traders watching closely for a potential pullback while bulls point to new foundry partnerships and deep-pocketed institutional backing as evidence of a long-term turnaround.

"What's Updog?" is a Community Led token.

UpDog

UpDog is capturing attention through a combination of sustained community momentum, aggressive whale accumulation, and successful organic growth efforts that have kept the token trending. Investors are actively discussing the project's multi-year history on Solana and its presence on the Jupiter strict list, with many looking for the next major leg up in its market trajectory.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Due to continued war and strikes in the middle-east region, Brent crude is expected to cross $100 per barrel resulting in a bull run in oil stocks.&nbsp;</li><li>Pennzoil Quaker State Company DBA SOPUS Products, a wholly owned subsidiary of Shell USA, will sell Jiffy Lube International to an affiliate of Monomoy Capital Partners for $1.3 billion.&nbsp;</li><li>Shell will retain its Pennzoil Quaker State, Rotella and other Shell lubricants brands.</li></ul>U.S. listed shares of Shell jumped more than 2% on Monday helped by rising oil prices as well as the oil producer divesting Jiffy Lube International and Premium Velocity Auto for $1.3 billion.&nbsp;Pennzoil Quaker State Company DBA SOPUS Products, a wholly owned subsidiary of Shell USA, Inc., that comprises Shell's United States lubricants business, has entered an agreement to sell Jiffy Lube International and its subsidiary Premium Velocity Auto business to an affiliate of Monomoy Capital Partners for $1.3 billion.&nbsp;Shell is the leading deep-water operator and largest producer of oil and gas in the U.S. Gulf of America and the largest buyer of U.S. LNG.&nbsp;<h2 class="st-heading-2">Details</h2>The sale includes the Jiffy Lube brand and a network of franchised stores which are owned and operated by independent franchisees, in addition to franchised stores that are owned and operated by PVA.&nbsp;Shell will retain its Pennzoil Quaker State, Rotella and other Shell lubricants brands, along with marketing, manufacturing and distribution of lubricants in the U.S. and Canada that serve consumer, commercial and industrial sectors."By capitalizing on a strong market opportunity, this divestment allows us to monetize an asset that is not central to Shell's lubricant's portfolio in the US and reinvest in opportunities that generate higher returns," said Machteld de Haan, President, Downstream, Renewables and Energy Solutions, Shell plc.The transaction is expected to close in the second half of 2026, subject to regulatory approval and other closing conditions.<h2 class="st-heading-2">Oil Stocks In Focus&nbsp;</h2>Oil stocks have been in focus ever since war broke out between U.S.-Israel and Iran as it has led to blockade of a critical sea route of Strait of Hormuz through which almost 20% of global crude and LNG passes.&nbsp;Due to continued war and strikes in the middle-east region, Brent crude is expected to cross $100 per barrel resulting in a bull run in oil stocks.&nbsp;<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment around SHEL trended in ‘neutral’ territory amid ‘high’ message volume.&nbsp;Shares in the company have risen 17% year-to-date.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.

The Shell logo displayed at a Shell gas station in Edmonton, Alberta, Canada, on March 22, 2025. 

Shell Stock Hits 52-Week High – Here’s Why

Rise in oil prices amid the ongoing conflict in the middle-east has spiked Brent crude and other energy product prices. 

Equity

Rise in oil prices amid the ongoing conflict in the middle-east has spiked Brent crude and other energy product prices. 


Shares of Swiss pharmaceutical giant Novartis AG were flat on Friday morning in heavy trading volume, despite the company reporting impressive quarterly results.&nbsp;Novartis posted core fourth-quarter (Q4) earnings per share (EPS) of $1.98, up from $1.53 last year, beating the consensus estimate of $1.80.&nbsp;Meanwhile, Q4 revenue reached $13.2 billion, surpassing the previous year’s $11.4 billion and analysts’ expectations of $12.84 billion.The company attributed its strong sales growth to its blockbuster heart-failure drug Entresto and arthritis medication Cosentyx.&nbsp;CEO Vas Narasimhan expressed optimism, stating, “In our first full year as a pure-play innovative medicines company, Novartis delivered one of the strongest financial performances in our history, growing sales 12% cc [constant currency basis] and core operating income 22% cc.”&nbsp;He added that the company achieved key innovation milestones, including new drug approvals and promising data that would drive growth in the mid- to long-term.Despite the upbeat results, retail sentiment on Stocktwits was mixed. Although message volume surged into ‘extremely bullish’ territory, sentiment remained ‘bearish,’ indicating some hesitation among retail traders.&nbsp;<figure class="image"><img style="aspect-ratio:1318/324;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/NVS_sentiment_and_message_volume_Jan_31_d92ad15174.png" alt="NVS sentiment and message volume Jan 31.png" width="1318" height="324"><figcaption>NVS sentiment and message volume Jan 31 as of 11:45 am ET | source: Stocktwits</figcaption></figure>Novartis is facing upcoming patent expirations for three key drugs, with Entresto expected to face generic competition in the U.S. mid-year.&nbsp;Additionally, two other top-selling drugs, Tasigna for leukemia and Promacta for a blood disorder, will face generics in the U.S.However, Narasimhan reassured investors, emphasizing the company’s “tremendous replacement power” and its ability to bring new treatments to market when patents on existing drugs expire.&nbsp;He also highlighted the company’s strong pipeline, with more than 30 assets that could drive differentiated growth over the long term, including updates on its cardiovascular drug candidate pelacarsen and a key late-stage trial this year.Looking ahead, Novartis forecasted FY25 net sales growth in the mid- to high-single-digit range, with core operating income expected to grow in the high single to low double-digit range.&nbsp;The company also proposed a 6.1% increase in its dividend to 3.50 Swiss francs per share for 2024.Although <a href="https://stocktwits.com/symbol/NVS">Novartis' stock</a> has lost 0.1% over the past 12 months, it is up more than 7% so far this year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Novartis company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

Novartis Gets Retail Chatting After Upbeat Q4, But Sentiment Stays Tepid Amid Volatile Trading

The company is facing upcoming patent expirations for three key drugs, with Entresto expected to face generic competition in the U.S. mid-year. 

U.S. shares of Sony Group Corp. (<a class="mention" data-mention="$SONY" data-symbol-id="SONY" href="https://stocktwits.com/symbol/SONY" target="_blank">$SONY</a>) surged over 7% pre-market Friday after the company reported a 69% jump in fiscal&nbsp;second-quarter (Q2) profit, driven by strength in its gaming and imaging divisions.&nbsp;Sony posted a profit of 338.5 billion yen (about $2.21 billion) on revenue of 2.91 trillion yen, up 3% year-over-year.&nbsp;The&nbsp;earnings per share (EPS) of 55.86 yen beat the consensus estimate of 39.84 yen, according to FactSet.The company saw robust performance in its Game &amp; Network Services and Imaging &amp; Sensing Solutions segments.&nbsp;Operating profit for the imaging business nearly doubled to 92.41 billion yen due to strong demand for image sensors, though Sony lowered its full-year sales and profit outlook for this segment.&nbsp;Despite selling only 3.8 million PlayStation 5 units this quarter — down from 4.9 million a year ago — Sony raised its annual profit forecast for the game division to 355.0 billion yen from 320.0 billion yen.Sony also launched its upgraded PlayStation 5 Pro this week, ahead of the holiday season, offering enhanced performance over the original 2020 model.&nbsp;The company revised its revenue forecast for the fiscal year ending March 2025, now expecting a 2.4% decline to 12.71 trillion yen, slightly better than the previously forecasted 3.2% drop.&nbsp;However, it maintained its outlook for a modest 1% increase in net profit to 980.0 billion yen.On Stocktwits, Sony was one of the top 30 trending tickers as of 7:30 am ET, reflecting heightened retail interest.&nbsp;<stembedurl>https://stocktwits.com/DT777/message/591690734</stembedurl>Still, Sony’s U.S.-listed shares are down over 2% year-to-date. Meanwhile, Tokyo-listed shares of the firm ended 1.2% higher on Friday.For updates and corrections, email&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="mailto:newsroom@stocktwits.com">newsroom@stocktwits.com</a>Read next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/usm-tds-stocks-get-upgraded-by-raymond-james/cJ45RFrRaJ">Are USM, TDS Trump Trades Now? Raymond James Upgrades Mid-Cap Telecom Stocks On Reduced Regulatory Risk</a>

Sony also launched its upgraded PlayStation 5 Pro this week, ahead of the holiday season.

Sony Stock Jumps Pre-Market As Profit Booms Nearly 70%: Retail Buzz Builds

Despite selling only 3.8 million PlayStation 5 units this quarter — down from 4.9 million a year ago — Sony raised its annual profit forecast.

AVIV
American Century ETF Trust - Avantis International Large Cap Value ETF

Feed

News

Sentiment

Fundamentals

Info

Latest AVIV News

AVIVAmerican Century ETF Trust - Avantis International Large Cap Value ETF